Suffering

Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
Thursday, July 29, 2021
Psychiatry, Abnormal psychology, Mental disorder, Psychiatric assessment, Psychiatric diagnosis, Psychopathology, Suffering, Psychology

The Company is scheduled to present at the conference at9:30 am Eastern Time the same day via webcast.

Key Points: 
  • The Company is scheduled to present at the conference at9:30 am Eastern Time the same day via webcast.
  • A live audio webcast of the conference presentation will be available online at the investor relations page of the Companys website at ir.neuronetics.com .
  • Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders.
  • NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japans national health insurance.

Former Sponsored Child Takes First Place in Compassion International and Baylor University's First-Ever Social Innovation Challenge

Retrieved on: 
Thursday, July 29, 2021
Applied ethics, Ethics, Human behavior, Kindness, Religious ethics, Suffering, Moral psychology, Compassion International, Compassion

At the age of six, Janeth was registered in Compassion International's child development program in her community.

Key Points: 
  • At the age of six, Janeth was registered in Compassion International's child development program in her community.
  • She met a Compassion tutor who was able to identify with her struggles at home and help her overcome them.
  • Today, Janeth was awarded first place in the first-ever innovation challenge from the Christian Collective for Social Innovation (CCSI), a joint initiative of Baylor University and Compassion International , and received a grand prize of $25,000.
  • Compassion International is a Christian child development organization working to release children from poverty in Jesus' name.

Branded Legacy, Inc. Launches New Delta 8 Product Line

Retrieved on: 
Wednesday, July 28, 2021
Nervous system, Branches of biology, Symptoms and signs, Acute pain, Nociception, Pain, Suffering

The Company adds the highly demanded Delta 8 products to its portfolio under Spikes CBDX brand.

Key Points: 
  • The Company adds the highly demanded Delta 8 products to its portfolio under Spikes CBDX brand.
  • Branded Legacys Vice President, Matthew Nichols quotes, Many of the retailers our sales team has contacted have requested Delta 8, and now we can fulfill this demand.
  • About Spikes CBDx: Spikes CBDx is a line of CBD products designed to assist athletes perform better, recover faster, and avoid injuries.
  • The CBD line also targets individuals who are looking for pain relief, better sleep, faster recovery and lowering inflammation.

XRHealth and Reducept Offer Patients Virtual Reality Therapy for Pain Management

Retrieved on: 
Monday, July 26, 2021
Pain, Branches of biology, Nervous system, Acute pain, Nociception, User interface techniques, Suffering, Virtual reality, Virtual reality therapy, Pain management, Chronic pain, Extended reality

BOSTON, July 26, 2021 /PRNewswire/ -- XRHealth ,the leader in extended reality and therapeutic applications,announced today that they are working with Reducept to expand their offering to patients for virtual reality therapy for pain management.

Key Points: 
  • BOSTON, July 26, 2021 /PRNewswire/ -- XRHealth ,the leader in extended reality and therapeutic applications,announced today that they are working with Reducept to expand their offering to patients for virtual reality therapy for pain management.
  • The virtual reality technology provides exercises that train people suffering from chronic pain on how to gain control over pain, potentially reducing the need for medication.
  • The Reducept VR Game trains the users' brain to create its own pain medication via digital psychological pain treatment.
  • XRHealth operates state-of-the-art therapeutic care Virtual Clinics, utilizing proprietary FDA and CE registered medical Extended Reality (XR) technology (virtual and augmented reality).

Neuronetics to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call

Retrieved on: 
Tuesday, July 20, 2021
Psychiatry, Branches of biology, Mind, Abnormal psychology, Mental disorder, Psychiatric assessment, Psychiatric diagnosis, Psychopathology, Suffering

MALVERN, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc.(NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release second quarter financial and operating results prior to market open on Tuesday, August 3, 2021.

Key Points: 
  • MALVERN, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc.(NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release second quarter financial and operating results prior to market open on Tuesday, August 3, 2021.
  • The Company will host a conference call to review its results at8:30 a.m. Eastern Timethe same day.
  • The conference call will be broadcast live in listen-only mode via a webcast on the Companys investor relations website at ir.neuronetics.com .
  • Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders.

2021 Report on Ocular Pain Drugs in Development - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Pharmaceutical, Health, Optical, Pain, Nervous system, Branches of biology, Nociception, Acute pain, Suffering

The "Ocular Pain (Eye Pain) (Central Nervous System) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ocular Pain (Eye Pain) (Central Nervous System) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Ocular Pain (Eye Pain), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Pain (Eye Pain) and features dormant and discontinued projects.
  • The report reviews key players involved in the development of Ocular Pain (Eye Pain) (Central Nervous System) therapeutics and enlists all their major and minor projects.

Multi-Center Study of SPRINT® PNS System for Chronic Low Back Pain Demonstrates Clinically Significant Improvements in Pain and Quality of Life

Retrieved on: 
Monday, July 12, 2021
Pain, Branches of biology, Clinical medicine, Nociception, Acute pain, Suffering, Chronic pain, Back pain, Transcutaneous electrical nerve stimulation, Amputation, Shoulder problem, Occipital nerve stimulation

73 percent of participants experienced a clinically significant reduction in average pain intensity with an average reduction in pain intensity of 58 percent among this group.

Key Points: 
  • 73 percent of participants experienced a clinically significant reduction in average pain intensity with an average reduction in pain intensity of 58 percent among this group.
  • Participants also reported substantial and statistically significant improvements in secondary endpoints including changes in health-related Quality of Life (QoL), patient global impression of change, and depression.
  • The system has been studied extensively for low back pain, shoulder pain, post-amputation pain, and chronic and acute post-operative pain, and iscleared for use up to 60 days.
  • Our SPRINT PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain.

Vivera Pharmaceuticals Supports Naomi Osaka's Stance On Prioritizing Mental Health

Retrieved on: 
Thursday, July 8, 2021
Psychiatry, Mind, Branches of biology, Mental health, Abnormal psychology, Mental disorder, Psychiatric diagnosis, Psychopathology, Suffering, Institute of Mental Health, Psychiatric and mental health nursing, Services for mental disorders

According to the National Institute of Mental Health, one in five adults in the U.S. suffer from mental health related conditions, a number exacerbated in the athletic community.

Key Points: 
  • According to the National Institute of Mental Health, one in five adults in the U.S. suffer from mental health related conditions, a number exacerbated in the athletic community.
  • Vivera recognizes the importance of mental health and understands that it is one of the greatest challenges society is combatting today.
  • To support treatment options for mental health disorders, Vivera created its neurosciences division, with a primary focus on psychiatric and neurological conditions.
  • The Company is currently developing three new medications targeted at treating mental health disorders.

Global Postoperative Pain Market to 2030 - Insight, Epidemiology and Market Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Health, Pharmaceutical, Nervous system, Branches of biology, Symptoms and signs, Nociception, Acute pain, Pain, Suffering

The "Postoperative Pain- Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Postoperative Pain- Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Postoperative Pain, historical and forecasted epidemiology as well as the Postoperative Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Postoperative Pain market report provides current treatment practices, emerging drugs, Postoperative Pain market share of the individual therapies, current and forecasted Postoperative Pain market Size from 2017 to 2030 segmented by seven major markets.
  • The Report also covers current Postoperative Pain treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

COVID pandemic heightens a lack of confidence amongst the public about which medicines to take and how to use them

Retrieved on: 
Thursday, July 8, 2021
Pain, Branches of biology, Nervous system, Acute pain, Nociception, Pharmaceuticals policy, Suffering, Over-the-counter drug

With more people now treating themselves at home, increasing numbers have questions and concerns when it comes tousing over the counter medicines the right way.

Key Points: 
  • With more people now treating themselves at home, increasing numbers have questions and concerns when it comes tousing over the counter medicines the right way.
  • One area of health that is particularly in focus is the management of pain.
  • Pain is one of the most common medicalareas in which peopleseek information about ways toself-manage with medication.
  • You can find a lot of information online, but it is not always easy to know which sources to trust.